Search results for "POSTMENOPAUSAL WOMEN"

showing 10 items of 58 documents

Sexual Function of Postmenopausal Women Addicted to Alcohol

2018

Introduction: Alcoholism impairs female sexual functions (decreased sex drive, reduced vaginal fluid, difficulty to experience orgasm). Aim: The aim of this study was to evaluate the course of perimenopausal period and sexual life of female alcoholics. Methods: 97 women at the age of 40&ndash

Adultsexual functioningHealth Toxicology and Mutagenesismedia_common.quotation_subjectPopulationlcsh:MedicineAlcohol abusemenopauseAlcoholOrgasmArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsSurveys and QuestionnairesPrevalenceHumansMedicine030212 general & internal medicineeducationmedia_commoneducation.field_of_study030219 obstetrics & reproductive medicinePostmenopausal womenalcoholismbusiness.industrylcsh:RAlcohol dependencePublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseasePostmenopauseMenopauseSexual Dysfunction PhysiologicalCross-Sectional StudieschemistryFemalebusinessSexual functionClinical psychologyInternational Journal of Environmental Research and Public Health
researchProduct

Muscular transcriptome in postmenopausal women with or without hormone replacement.

2007

The loss of muscle mass and strength with aging is well characterized, but our knowledge of the molecular mechanisms underlying the development of sarcopenia remains incomplete. Although menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. Furthermore the knowledge of the global transcriptional changes that take place in skeletal muscle in relation to estrogen status has thus far been completely lacking. We used a randomized double-blinded study design together with an explor…

Agingmedicine.medical_specialtyvaihdevuodetmedicine.drug_classmenopaussiBiologysarcopeniaTranscriptomeInternal medicinemedicineHumanssarkopeniaRNA Messengermuscular transcriptomeMuscle SkeletalOligonucleotide Array Sequence AnalysishormonikorvaushoitolihastranskriptomiRegulation of gene expressionPostmenopausal womenGene Expression ProfilingEstrogen Replacement TherapySkeletal muscleMiddle Agedmedicine.diseaseMenopauseGene expression profilingPostmenopausehormone replacement therapyEndocrinologymedicine.anatomical_structureGene Expression RegulationReceptors EstrogenEstrogenSarcopeniaFemalesense organsGeriatrics and GerontologyRejuvenation research
researchProduct

Apo E phenotypes and plasma triglycerides in postmenopausal women with hormone replacement therapy

2000

Apolipoprotein Emedicine.medical_specialtyEndocrinologyPostmenopausal womenbusiness.industryInternal medicinemedicineHormone replacement therapyCardiology and Cardiovascular MedicinebusinessPhenotypeAtherosclerosis
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

Physical Activity Is Related with Cartilage Quality in Women with Knee Osteoarthritis

2017

Purpose To study the relationship between 12-month leisure-time physical activity (LTPA) level and changes in estimated biochemical composition of tibiofemoral cartilage in postmenopausal women with mild knee osteoarthritis (OA). Methods Originally, 87 volunteer postmenopausal women, age 60 to 68 yr, with mild knee OA (Kellgren Lawrence I/II and knee pain) participated in a randomized controlled, 4-month aquatic training trial (RCT), after which 76 completed the 12-month postintervention follow-up period. Self-reported LTPA was collected along the 12-month period using a diary from which MET task hours per month were calculated. Participants were divided into MET task hour tertiles: 1, lowe…

Cartilage ArticularSelf-Assessmentmedicine.medical_specialtynivelrikkoKnee Jointpolvetquantitative magnetic resonance imagingPhysical activitypostmenopausal womenPhysical Therapy Sports Therapy and RehabilitationrustoOsteoarthritisKnee Jointleisure-time physical activity03 medical and health sciences0302 clinical medicinemedicineBiochemical compositionHumansOrthopedics and Sports Medicineta315ExerciseVolunteerGlycosaminoglycans030203 arthritis & rheumatologyPostmenopausal womenbusiness.industryCartilageta3141Cardiorespiratory fitnessfollow-up study030229 sport sciencesMiddle AgedOsteoarthritis Kneemedicine.diseaseMagnetic Resonance Imagingcartilage compositionmedicine.anatomical_structureCardiorespiratory FitnessPhysical therapyMETFemaleseurantatutkimusbusinesshuman activitiesfyysinen aktiivisuusFollow-Up Studies
researchProduct

Association between radiography-based subchondral bone structure and MRI-based cartilage composition in postmenopausal women with mild osteoarthritis

2016

Summary Objective Our aim was to investigate the relation between radiograph-based subchondral bone structure and cartilage composition assessed with delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC) and T 2 relaxation time. Design Ninety-three postmenopausal women (Kellgren–Lawrence grade 0: n  = 13, 1: n  = 26, 2: n  = 54) were included. Radiograph-based bone structure was assessed using entropy of the Laplacian-based image ( E Lap ) and local binary patterns ( E LBP ), homogeneity indices of the local angles (HI Angles,mean , HI Angles,Perp , HI Angles,Paral ), and horizontal (FD Hor ) and vertical fractal dimensions (FD Ver ). Mean dGEMRIC index and T 2 relax…

Cartilage ArticularpolvetRadiographyluuContrast MediaGadoliniumrustoOsteoarthritisSeverity of Illness Indexbone030218 nuclear medicine & medical imaging0302 clinical medicinemagneettitutkimusOrthopedics and Sports Medicineta315kneesradiographersta3141AnatomyMiddle AgedOsteoarthritis KneeMagnetic Resonance ImagingPostmenopauseTrabecular bonemedicine.anatomical_structureSubchondral boneFemaleradiographyMRInivelrikkobone structureBiomedical Engineering03 medical and health sciencesRheumatologymedicineHumansAgedta217030203 arthritis & rheumatologyPostmenopausal womenTibiabusiness.industryCartilageröntgentutkimusDelayed Gadolinium Enhanced Magnetic Resonance Imaging of Cartilagemedicine.diseasecartilage compositionosteoarthritisCross-Sectional StudiesbusinessBone structureOsteoarthritis and Cartilage
researchProduct

Menopause and diabetes: EMAS clinical guide

2018

Abstract Introduction Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM. Aims To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM. Materials and methods Literature review and consensus of experts’ opinions. Results and conclusion Metabolic changes during the menopausal transition include an increase in and the central redis…

ESTROGEN REPLACEMENTmedicine.medical_specialtyHORMONE-REPLACEMENT THERAPYendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismDiseaseDydrogesteroneGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine3123 Gynaecology and paediatricsRisk FactorsInternal medicineDiabetes mellitusType 2 diabetes mellitusDiabetes MellitusmedicineHumansNATURAL MENOPAUSEMenopausal hormone therapy; Menopause; Type 2 diabetes mellitus; Estrogen Replacement Therapy; Female; Humans; Incidence; Risk Factors; Diabetes Mellitus Type 2; MenopauseESTRADIOLMETABOLIC SYNDROME030219 obstetrics & reproductive medicineProgestogenINSULIN SENSITIVITYbusiness.industryIncidenceEstrogen Replacement TherapyENERGY-EXPENDITUREnutritional and metabolic diseasesObstetrics and GynecologyType 2 Diabetes MellitusHormone replacement therapy (menopause)medicine.disease3. Good healthMenopausePOSTMENOPAUSAL WOMENDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineRISK-FACTORSFemaleHEALTHMenopauseMetabolic syndromebusinessType 2Menopausal hormone therapymedicine.drug
researchProduct

A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tableton Upper Gastrointestinal Safety and Medicati…

2021

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeuticoption for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. Inthis multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women(PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent(ALN-EFF) tablet (Binosto®) and followed for 12  3 months. Information was collected on adverse events (AEs), medication errors,persistence, and compliance using the Morisky-Green questionnai…

GASTROINTESTINAL ADVERSE EVENTSPOSTMENOPAUSAL WOMENEFFERVESCENTOSTEOPOROSISALENDRONATE
researchProduct

A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medicat…

2021

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women (PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent (ALN-EFF) tablet (Binosto®) and followed for 12 ± 3 months. Information was collected on adverse events (AEs), medication errors, persistence, and compliance using the Morisky-Green questi…

GASTROINTESTINAL ADVERSE EVENTSmedicine.medical_specialtyAgingNauseaEndocrinology Diabetes and MetabolismOsteoporosisDiseases of the musculoskeletal systemOSTEOPOROSISInternal medicineparasitic diseasesmedicineClinical endpointOrthopedics and Sports MedicineCumulative incidenceAdverse effectALENDRONATEOrthopedic surgerybusiness.industryalendronate; effervescent; gastrointestinal adverse events; osteoporosis; postmenopausal womenEvaluation of treatments and therapeutic interventionsEFFERVESCENTOriginal Articlesmedicine.diseaseConfidence intervalDiscontinuationTolerabilityPOSTMENOPAUSAL WOMENRC925-9356.1 PharmaceuticalsOsteoporosisOriginal ArticlePatient Safetymedicine.symptombusinessDigestive DiseasesRD701-811JBMR Plus
researchProduct

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct